Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness

Cardiovascular Research

Volumn 77, Issue 2, 2008, Pages 371-379

  Van Den Bergh, An ^a   Vanderper, Annelies ^a   Vangheluwe, Peter ^a   Desjardins, Fanny ^b   Nevelsteen, Ines ^a   Verreth, Wim ^a   Wuytack, Frank ^a   Holvoet, Paul ^a   Flameng, Willem ^a   Balligand, Jean Luc ^b   Herijgers, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Apoptosis; Athcrosclcrosis; Contractile function; Diabetes; SR (function)

Indexed keywords

LEPTIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; DYSLIPIDEMIA; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE RELAXATION; HEART OUTPUT; IN VIVO CULTURE; KNOCKOUT MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RIGIDITY; SARCOPLASMIC RETICULUM;

ANIMALS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIUM; RECEPTORS, LDL; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; VENTRICULAR FUNCTION, LEFT;

EID: 38849184604     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvm001     Document Type: Article

References (31)

1. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004;25:543- 567.
2. Van Den Bergh A, Flameng W, Herijgers P. Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. Eur J Heart Fail 2006;8:777-783.
3. Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 2002;283:H976-H982.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-31421.
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
6. Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W, Stengel D, Ninio E, Navab M, Mackness B, Mackness M, Holvoet P. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003;107:1640-1646.
7. Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabiles N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P. Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004;110:3259-3269.
8. Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca(2+)-ATPase and myosin heavy chain isozyme switch. Diabetologia 2006;49:1434- 1446.
9. Barouch LA, Gao D, Chen L, Miller KL, Xu W, Phan AC, Kittleson MM, Minhas KM, Berkowitz DE, Wei C, Hare JM. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ Res 2006;98:119-124.
10. 2+ ATPase 2 (SERCA2) activity: cell biological implications. Cell Calcium 2005;38:291-302.
11. Huang Y, Walker KE, Hanley F, Narula J, Houser SR, Tulenko TN. Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation 2004;109:97-102.
12. Carabello BA. Evolution of the study of left ventricular function: everything old is new again. Circulation 2002;105:2701-2703.
13. -/- mice in vivo. Circulation 2003;107:2480-2486.
14. 2+-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. Circ Res 2001;89:838-846.
15. 2(+)-pump isoforms and of phospholamban in pig smooth-muscle tissues. Biochem J 1990;271:649-653.
16. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003;4:566-577.
17. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, Collen D, Carmeliet P, Moons L. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 2005;166:15-25.
18. Kass DA, Maughan WL. From 'Emax' to pressure-volume relations: a broader view. Circulation 1988;77:1203-1212.
19. De Simone G, Devereux RB, Celentano A, Roman MJ. Left ventricular chamber and wall mechanics in the presence of concentric geometry. J Hypertens 1999;17:1001-1006.
20. Shimizu G, Zile MR, Blaustein AS, Gaasch WH. Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements. Circulation 1985;71:266-272.
21. Mattiazzi A, Mundina-Weilenmann C, Vittone L, Said M, Kranias EG. The importance of the Thr17 residue of phospholamban as a phosphorylation site under physiological and pathological conditions. Braz J Med Biol Res 2006;39:563-572.
22. Minhas KM, Khan SA, Raju SV, Phan AC, Gonzalez DR, Skaf MW, Lee K, Tejani AD, Saliaris AP, Barouch LA, O'Donnell CP, Emala CW, Berkowitz DE, Hare JM. Leptin repletion restores depressed {beta}-adrenergic contractility in ob/ob mice independently of cardiac hypertrophy. J Physiol 2005;565:463- 474.
23. Perreault CL, Shannon RP, Shen YT, Vatner SF, Morgan JP. Excitation-contraction coupling in isolated myocardium from dogs with compensated left ventricular hypertrophy. Am J Physiol 1994;266:H2436-H2442.
24. Bustamante JO, Ruknudin A, Sachs F. Stretch-activated channels in heart cells: relevance to cardiac hypertrophy. J Cardiovasc Pharmacol 1991;17(Suppl. 2):S110-S113.
25. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228.
26. 2+ response amplitude and duration. Nature 1997;386:855-858.
27. Chen CH, Nakayama M, Nevo E, Fetics BJ, Maughan WL, Kass DA. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 1998;32:1221-1227.
28. Segers P, Stergiopulos N, Westerhof N. Relation of effective arterial elastance to arterial system properties. Am J Physiol Heart Circ Physiol 2002;282:H1041-H1046.
29. Herrera MF, Deitel M. Cardiac function in massively obese patients and the effect of weight loss. Can J Surg 1991;34:431-434.
30. Dart AM, Kingwell BA. Pulse pressure - a review of mechanisms and clinical relevance. J Am Coll Cardiol 2001;37:975-984.
31. Hundley WG, Kitzman DW, Morgan TM, Hamilton CA, Darty SN, Stewart KP, Herrington DM, Link KM, Little WC. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 2001;38:796-802.